+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease



Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease



Therapeutic Apheresis and Dialysis 17(4): 363-367



Chronic kidney disease (CKD) is common and several factors affect its progression to end-stage renal disease (ESRD). The main goal of our study was to assess the influence of underlying kidney disease and some other important factors during the time of CKD progression to ESRD. A retrospective study of 91 patients (57 men, 34 women; average age 57.7 ± 13.2 years) was carried out. Patients were monitored at least one month before the first renal replacement treatment (RRT). Estimated glomerular filtration rate (eGFR) at first referral to nephrologist was determined by Modification of Diet in Renal Disease equation. Proteinuria was assessed semiquantitatively with dipsticks. Thirty-five patients (38.5%) had diabetic nephropathy (DN), 21 (23.1%) hypertensive nephrosclerosis (HN), 21 (23.1%) adult polycystic kidney disease (APKD) and 14 (15.4%) immunoglobulin A nephropathy (IgAN). Average eGFR at first referral for DN patients was 20.1, and then 23.4 for HN, 35.5 for APKD, and 36.4 mL/min per 1,73 m(2) for IgAN patients. Average time between first nephrological visit and first RRT was 28.4 months for DN patients, 41 for HN, 80.8 for APKD, and 70.1 for IgAN patients. Comparison of all four groups of CKD patients showed that in patients with APKD and IgAN impairment of kidney function to ESRD had progressed statistically significantly slower (P < 0.001). When eGFR at referral, proteinuria, smoking, and renin-angiontensin-aldosterone blockade treatment had been added into the model, patients with APKD and IgAN had a statistically significant longer period between first nephrological visit and first RRT (P < 0.026). In comparison with patients with other underlying causes of CKD, patients with APKD and IgAN had a statistically significant slower progression rate of CKD to ESRD.

(PDF emailed within 0-6 h: $19.90)

Accession: 037402565

Download citation: RISBibTeXText

PMID: 23931872

DOI: 10.1111/1744-9987.12079


Related references

Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience. Clinical and Experimental Nephrology 17(3): 345-351, 2014

Outcomes of stage 3-5 chronic kidney disease before end-stage renal disease at a single center in Taiwan. Nephron. Clinical Practice 109(3): C109-C118, 2008

Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care. Plos One 10(5): E0127071, 2016

Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study. Clinical and Experimental Nephrology 2018, 2018

Erratum: Perrone RD, Mouksassi M-S, Romero K, et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep. 2017;2:442-450. Kidney International Reports 3(4): 1015-1015, 2018

End-stage renal disease after kidney donation: a single-center experience. Transplantation Proceedings 40(5): 1315-1318, 2008

End-stage renal disease among living-kidney donors: single-center experience. Experimental and Clinical Transplantation 9(1): 14-19, 2011

Fp339The Experience Of Chronic Kidney Disease Patients: The Results Of The 2017 Uk Renal Registry / Kidney Care Uk Chronic Kidney Disease Patient Reported Experience Measure. Nephrology Dialysis Transplantation 33(Suppl_1): i145-i146, 2018

Chronic kidney disease and end-stage renal disease in disadvantaged communities of North America: an investigational challenge to limit disease progression and cardiovascular risk. Clinical Nephrology 86 (13): 37-40, 2016

Use of the Kidney Failure Risk Equation to Determine the Risk of Progression to End-stage Renal Disease in Children With Chronic Kidney Disease. JAMA Pediatrics 172(2): 174-180, 2017

A single center kidney transplant experience among ten Caucasian females with end-stage renal disease due to scleroderma
. Clinical Nephrology 88(1): 40-44, 2017

Sp316The Higher Mortality Is Associated With Heart Valve Disease In End Stage Kidney Disease; A Single Center Experience. Nephrology Dialysis Transplantation 33(Suppl_1): i450-i451, 2018

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports 2(3): 442-450, 2017

Conservatively managed patients with stage 5 chronic kidney disease--outcomes from a single center experience. Qjm 102(8): 547-554, 2010

Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clinical Science 130(14): 1147-1163, 2017